Patents by Inventor Dong-Gyu Jo
Dong-Gyu Jo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230241119Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating a brain disease, comprising a stem cell-derived exosome surface-modified with a compound capable of binding to dopamine receptors or L-amino acid transporters as an active ingredient. The stem cell-derived exosome according to the present disclosure selectively binds to dopamine receptors (D2) overexpressed as autoreceptors in dopaminergic neurons in the substantia nigra through surface modification. Thereby, local accumulation in dopaminergic neurons is possible. In addition, it was identified that the stem cell-derived exosome exhibited an excellent neuron protective effect and neuron death inhibitory effect. Accordingly, the surface-modified stem cell-derived exosome according to the present disclosure is expected to be usefully used as a composition for preventing or treating a brain disease including Parkinson's disease and Alzheimer's disease.Type: ApplicationFiled: February 3, 2023Publication date: August 3, 2023Applicant: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITYInventors: Jae Hyung PARK, Dong Gyu JO, Sol SHIN, Jae Hoon SUL
-
Publication number: 20230227828Abstract: The present invention relates to a composition for preventing or treating Alzheimer’s disease, containing an inhibitor of ATL2, and a method of diagnosing the disease based on the measurement of the ATL2. In the present invention, it was found that PS1 mutants may result in mitochondrial dysfunction, such as increased binding between endoplasmic reticulum and mitochondria, increased mitochondrial ROS production, decreased mitochondrial membrane potential, decreased ATP production, decreased complex I activity, and decreased peroxidase activity, in brain glioma cells and that the PS1 mutants may abnormally increase the binding between endoplasmic reticulum and mitochondria by elevating the expression of the ATL2 in the brain. In addition, when the ATL2 was knocked down, it was observed that the binding between endoplasmic reticulum and mitochondria was lowered and that the expression of the ATL2 was elevated in the brains of Alzheimer’s disease animal models and patients.Type: ApplicationFiled: December 27, 2022Publication date: July 20, 2023Applicant: Research & Business Foundation Sungkyunkwan UniversityInventors: Dong Gyu JO, Ji Hoon HAN
-
Publication number: 20230211010Abstract: The present disclosure relates to an exosome comprising a photocleavable protein and a use thereof, and the exosome according to the present disclosure contains a fusion protein comprising a blue fluorescent protein (TagBFP), a photocleavable protein (mMaple3), and an exosome-specific marker protein (CD9), and it has been found that when light of 405 nm is irradiated to the exosome, the photocleavable protein, mMaple3 is cleaved and thereby the blue fluorescent protein in the exosome can be delivered into a target cell. In addition, it has been found that Cre protein in the exosome can be delivered into an animal organ, when light of 405 nm is irradiated to an exosome containing Cre fusion protein (Cre-mMaple3-CD9). Therefore, the exosome containing the photocleavable protein according to the present disclosure is expected to be useful in the protein treatment field by safely and efficiently delivering various therapeutic proteins into cells.Type: ApplicationFiled: February 8, 2021Publication date: July 6, 2023Inventors: Dong Gyu JO, Jihoon Han, Jaehoon Sul
-
Publication number: 20230047434Abstract: A composition, for inducing chondrocyte differentiation or regenerating cartilage tissue or both, includes exosomes derived from stem cells differentiating into chondrocytes.Type: ApplicationFiled: August 24, 2022Publication date: February 16, 2023Inventors: Yong Woo CHO, Ji Suk CHOI, Chang Hee WOO, Young Chan CHOI, Dong Gyu JO
-
Publication number: 20220281805Abstract: A lobamide compound according to an embodiment of the present disclosure is represented by Formula 1. The lobamide compound has excellent PTP-1B inhibitory activity that is far higher than that of conventional lobaric acid derivatives and which can be orally administered, and thus is very effective in the prevention or treatment of diabetes or obesity through oral administration.Type: ApplicationFiled: August 14, 2020Publication date: September 8, 2022Inventors: Joung Han YIM, Il Chan KIM, Se Jong HAN, Tai Kyoung KIM, Dong Gyu JO, Hyun Cheol OH, Ha Ju PARK, Seul Ki MIN, Sung Jin KIM, Pil Sung KANG, Min Ju KIM, Jung Eun KIM, Kyung Hee KIM, Ju Mi HONG
-
Publication number: 20210161969Abstract: The present disclosure relates to a composition for preventing or treating acute liver failure using exosomes. The inventors of the present disclosure have experimentally identified in an acute liver failure animal model that mice to which exosomes derived from adipose-derived mesenchymal stem cells were administered survived at higher rates, had improved levels of aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) and exhibited superior apoptosis-inhibiting and anti-inflammatory effects, compared with mice to which the exosomes were not administered. Thus, the composition of the present disclosure can be usefully used for development of medical products, foods, etc. for preventing, alleviating or treating acute liver failure.Type: ApplicationFiled: July 27, 2018Publication date: June 3, 2021Inventors: Dong-Gyu JO, Jae-Hoon SUL, Hark-Kyun KIM, Eun-Ae KIM, Yong-Woo CHO
-
Patent number: 10993434Abstract: The present invention relates to an exopolysaccharide derived from Pseudoalteromonas sp. strain CY01 (KCTC 12867BP) which is a novel strain living in the polar regions, and to a composition for cryoprotection of cells, which contains the exopolysaccharide. The exopolysaccharide of the present invention has an excellent ability to cryoprotect cells, and shows no cytotoxicity. Thus, the inventive exopolysaccharide can substitute for conventional cryoprotective agents that show cytotoxicity when used at high concentrations.Type: GrantFiled: December 8, 2017Date of Patent: May 4, 2021Assignee: Korea Institute of Ocean Science and TechnologyInventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Ui Joung Youn, Hong Kum Lee, Sung Jin Kim, Pil-Sung Kang, Jung Eun Kim, Tai Kyoung Kim, Ha Ju Park, Jin Haeng Song, Min Ju Kim, Ju Mi Hong, Dong-Gyu Jo
-
Publication number: 20180325101Abstract: The present invention relates to an exopolysaccharide derived from Pseudoalteromonas sp. strain CY01 (KCTC 12867BP) which is a novel strain living in the polar regions, and to a composition for cryoprotection of cells, which contains the exopolysaccharide. The exopolysaccharide of the present invention has an excellent ability to cryoprotect cells, and shows no cytotoxicity. Thus, the inventive exopolysaccharide can substitute for conventional cryoprotective agents that show cytotoxicity when used at high concentrations.Type: ApplicationFiled: December 8, 2017Publication date: November 15, 2018Inventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Ui Joung Youn, Hong Kum Lee, Sung Jin Kim, Pil-Sung Kang, Jung Eun Kim, Tai Kyoung Kim, Ha Ju Park, Jin Haeng Song, Min Ju Kim, Ju Mi Hong, Dong-Gyu Jo
-
Patent number: 9968576Abstract: The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an inflammasome and BACE1 expression inhibitory activity. Ramalin according to the present invention has an effect of improving a cognitive ability by inhibiting the expression of an inflammatory factor, which contains an NLRP inflammasome protein, and BACE1, and is thus useful for preventing or treating memory disorder and neurodegenerative diseases.Type: GrantFiled: October 24, 2014Date of Patent: May 15, 2018Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGYInventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Dong-Gyu Jo
-
Publication number: 20170304244Abstract: The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an inflammasome and BACE1 expression inhibitory activity. Ramalin according to the present invention has an effect of improving a cognitive ability by inhibiting the expression of an inflammatory factor, which contains an NLRP inflammasome protein, and BACE1, and is thus useful for preventing or treating memory disorder and neurodegenerative diseases.Type: ApplicationFiled: October 24, 2014Publication date: October 26, 2017Inventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Dong-Gyu Jo
-
Publication number: 20170296590Abstract: A composition, for inducing chondrocyte differentiation or regenerating cartilage tissue or both, includes exosomes derived from stem cells differentiating into chondrocytes.Type: ApplicationFiled: July 5, 2017Publication date: October 19, 2017Inventors: Yong Woo CHO, Ji Suk CHOI, Chang Hee WOO, Young Chan CHOI, Dong Gyu JO
-
Patent number: 9549942Abstract: The present disclosure relates to a pharmaceutical composition, a health functional food composition, and a method for preventing or treating a brain disease or diabetes. The pharmaceutical composition, health functional food composition, and method includes at least one active ingredient that is chlorhexidine, thioguanosine, mebendazole, fenbendazole, colchicine, farnesol, trimethobenzamide hydrochloride, disulfuram, azathioprine, mebeverine hydrochloride, zaprinast, tosufloxacin hydrochloride, efavirenz, thiostrepton, probenecid, entacapone, harmine hydrochloride, flunisolide, thimerosal, hexestrol, sulfaquinoxaline sodium salt, monensin sodium salt, raloxifene hydrochloride, 2-chloropyrazine, or topotecan.Type: GrantFiled: July 14, 2014Date of Patent: January 24, 2017Assignee: Research & Business Foundation Sungkyunkwan UniversityInventors: Dong Gyu Jo, Jong Sung Park, Youngkwang Youn, Yuri Choi, Ui Jeong Yun
-
Publication number: 20160199367Abstract: Provided is a composition for preventing or treating stroke, and more particularly, a pharmaceutical composition for preventing or treating stroke, which contains a peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) inhibitor as an active ingredient. The Pin1 inhibitor has a neuroprotective effect in which production of NICD1, which is a Notch1 signaling activation product activated in ischemic stroke, is regulated, and cerebral infarction and deficits of neuronal cells triggered by ischemic stroke and neuronal cell death are reduced, and thus can be useful in preventing or treating stroke and also useful in treating a cerebrovascular disease and stroke-associated dementia.Type: ApplicationFiled: August 17, 2015Publication date: July 14, 2016Applicant: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITYInventors: Dong Gyu JO, Sang-Ha BAIK
-
Publication number: 20150018297Abstract: The present disclosure relates to a pharmaceutical composition, a health functional food composition, and a method for preventing or treating a brain disease or diabetes. The pharmaceutical composition, health functional food composition, and method includes at least one active ingredient that is chlorhexidine, thioguanosine, mebendazole, fenbendazole, colchicine, farnesol, trimethobenzamide hydrochloride, disulfuram, azathioprine, mebeverine hydrochloride, zaprinast, tosufloxacin hydrochloride, efavirenz, thiostrepton, probenecid, entacapone, harmine hydrochloride, flunisolide, thimerosal, hexestrol, sulfaquinoxaline sodium salt, monensin sodium salt, raloxifene hydrochloride, 2-chloropyrazine, or topotecan.Type: ApplicationFiled: July 14, 2014Publication date: January 15, 2015Applicant: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITYInventors: Dong Gyu JO, Jong Sung PARK, Youngkwang YOUN, Yuri CHOI, Ui Jeong YUN
-
Patent number: 8846750Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: GrantFiled: July 1, 2011Date of Patent: September 30, 2014Assignee: Korea Ocean Research and Development InstituteInventors: Joung Han Yim, Il Chan Kim, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Bhattarai Hari Datta, Jung Eun Kim, Tai Kyoung Kim, Hyun Cheol Oh, Dong-Gyu Jo, Cheolsoon Lee, Keun-Sik Kim, Pyung Cheon Lee, Mi Ra Park, Yu-Kyung Park, Sung Jin Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park
-
Patent number: 8703814Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: GrantFiled: May 22, 2013Date of Patent: April 22, 2014Assignee: Korea Ocean Research and Development InstituteInventors: Joung Han Yim, Il Chan Kim, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Bhattarai Hari Datta, Jung Eun Kim, Tai Kyoung Kim, Hyun Cheol Oh, Dong-Gyu Jo, Cheolsoon Lee, Keun-Sik Kim, Pyung Cheon Lee, Mi Ra Park, Yu-Kyung Park, Sung Jin Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park
-
Patent number: 8697745Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: GrantFiled: May 22, 2013Date of Patent: April 15, 2014Assignee: Korea Ocean Research InstituteInventors: Joung Han Yim, Il Chan Kim, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Bhattarai Hari Datta, Jung Eun Kim, Tai Kyoung Kim, Hyun Cheol Oh, Dong-Gyu Jo, Cheolsoon Lee, Keun-Sik Kim, Pyung Cheon Lee, Mi Ra Park, Yu-Kyung Park, Sung Jin Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park
-
Publication number: 20140094514Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: ApplicationFiled: May 22, 2013Publication date: April 3, 2014Applicant: Korea Ocean Research and Development InstituteInventors: Joung Han YIM, Il Chan KIM, Doc Kyu KIM, Se Jong HAN, Hyoung Seok LEE, Bhattarai HARI DATTA, Jung Eun KIM, Tai Kyoung KIM, Hyun Cheol OH, Dong-Gyu JO, Cheolsoon LEE, Keun-Sik KIM, Pyung Cheon LEE, Mi Ra PARK, Yu-Kyung PARK, Sung Jin KIM, Pil-Sung KANG, Heeyong PARK, Ha Ju PARK
-
Publication number: 20140073614Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: ApplicationFiled: May 22, 2013Publication date: March 13, 2014Applicant: Korea Ocean Research and Development InstituteInventors: Joung Han YIM, Il Chan KIM, Doc Kyu KIM, Se Jong HAN, Hyoung Seok LEE, Bhattarai HARI DATTA, Jung Eun KIM, Tai Kyoung KIM, Hyun Cheol OH, Dong-Gyu JO, Cheolsoon LEE, Keun-Sik KIM, Pyung Cheon LEE, Mi Ra PARK, Yu-Kyung PARK, Sung Jin KIM, Pil-Sung KANG, Heeyong PARK, Ha Ju PARK
-
Publication number: 20130261174Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: ApplicationFiled: July 1, 2011Publication date: October 3, 2013Applicant: KOREA OCEAN RESEARCH AND DEVELOPMENT INSTITUTEInventors: Joung Han Yim, Il Chan Kim, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Bhattarai Hari Datta, Jung Eun Kim, Tai Kyoung Kim, Hyun Cheol Oh, Dong-Gyu Jo, Cheolsoon Lee, Keun-Sik Kim, Pyung Cheon Lee, Mi Ra Park, Yu-Kyung Park, Sung Jin Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park